Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Why now
Thesis: Early preclinical antiviral data, unproven in humans
Catalyst to watch: IND filing or clinical trial start
Main risk: Preclinical results often fail in humans
Why it matters
Preclinical PK data for an intranasal coronavirus program is early-stage and not yet clinically validated.
Details
Once-Weekly Intranasal Potential: Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue. Addressing Endemic Coronaviruses: DCOY-CoV is designed to protect against endemic human...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-29 11:30 UTC